Are there any drug interactions between trazodone and Bosulif (bosutinib)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Trazodone and Bosulif (Bosutinib) Drug Interaction

There is no direct pharmacokinetic interaction between trazodone and bosutinib, but caution is warranted due to potential additive QT prolongation risk and the fact that both drugs can affect cardiac function.

Key Interaction Considerations

CYP3A4 Metabolism Pathway

Bosutinib is primarily metabolized by CYP3A4 1, 2, while trazodone is also a CYP3A4 substrate. However, neither drug is a strong CYP3A4 inhibitor or inducer at therapeutic doses, so clinically significant pharmacokinetic interactions through this pathway are unlikely.

Critical Safety Concerns

The FDA label for bosutinib explicitly warns about cardiac toxicity, including cardiac failure, left ventricular dysfunction, and cardiac ischemic events 3. Patients should be monitored for:

  • Shortness of breath
  • Weight gain
  • Fluid retention
  • Signs of cardiac ischemia

Trazodone carries a known risk of QT prolongation, particularly at higher doses. When combined with bosutinib (which can cause cardiovascular toxicity), there is theoretical concern for additive cardiac effects.

Practical Management Recommendations

You can use these medications together with appropriate monitoring:

  • Baseline ECG before initiating combination therapy
  • Monitor for cardiac symptoms including palpitations, syncope, or dyspnea
  • Avoid other QT-prolonging agents when possible
  • Consider dose adjustment if cardiac symptoms emerge
  • Regular cardiac monitoring in patients with pre-existing cardiac disease

Drug Interaction Warnings from FDA Label

The bosutinib FDA label states that "BOSULIF and certain other medicines, including over the counter medications or herbal supplements can interact with each other and may alter the effects of BOSULIF" 3. However, trazodone is not specifically listed as a contraindicated or cautionary medication 3.

Important Caveats

  • Strong CYP3A4 inhibitors and inducers should be avoided with bosutinib 3, but trazodone does not fall into these categories
  • Proton pump inhibitors should be avoided; use short-acting antacids or H2 blockers instead 3
  • Bosutinib can inhibit drug transporters (OCT2, MATE1, BCRP) 4, but trazodone is not a significant substrate of these transporters

Monitor closely for cardiac symptoms and consider cardiology consultation if the patient has pre-existing cardiac disease or is on multiple medications affecting cardiac conduction.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.